Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenegermin duration in dry eye-associated neurotrophic keratitis
NCT06947850Phase 4Active, not recruiting
- Sponsor
- Toyos Clinic
- Start
- Jan 2023
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cenegermin in neurotrophic keratitis (NK) (2 arms), sponsored by Toyos Clinic. Primary endpoint: Assessment of Longer Duration of Treatment at 8 months. Started Jan 2023; status: active, not recruiting.
02
Drugs
cenegermin
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on NCT06947850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947850.